First In-Human Medical Imaging with a PASylated (89)Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

PURPOSE: PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment ((89)Zr∙Df-HER2-Fab-PAS(200)) for the molecular imaging of tumor-related HER2 expressio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nucl Med Mol Imaging
Autores principales: Richter, Antonia, Knorr, Karina, Schlapschy, Martin, Robu, Stephanie, Morath, Volker, Mendler, Claudia, Yen, Hsi-Yu, Steiger, Katja, Kiechle, Marion, Weber, Wolfgang, Skerra, Arne, Schwaiger, Markus
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7198682/
https://ncbi.nlm.nih.gov/pubmed/32377263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13139-020-00638-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares